Stay updated with breaking news from Strauss Carpenter Level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual...
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia for up to one year Presentation of study design for potentially...
Ad hoc announcement pursuant to Art. 53 LR Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia...